Tore K Kvien

Comparison of Upper Gastrointestinal Toxicity of Rofecoxib and Naproxen in Patients with Rheumatoid Arthritis

Claire Bombardier, Loren Laine, Alise Reicin et al. · New England Journal of Medicine · 2000 · 4K citations · Full text

EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update

Josef S Smolen, Robert Landewé, Ferdinand C. Breedveld et al. · Annals of the Rheumatic Diseases · 2013 · 1.8K citations · Full text

EULAR evidence-based recommendations for cardiovascular risk management in patients with rheumatoid arthritis and other forms of inflammatory arthritis

M.J. Peters, Deborah Symmons, David McCarey et al. · Annals of the Rheumatic Diseases · 2009 · 1.3K citations · Full text

American College of Rheumatology/European League Against Rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials

David T. Felson, Josef S Smolen, George A. Wells et al. · Arthritis & Rheumatism · 2011 · 1K citations · Full text

Switching from originator infliximab to biosimilar CT-P13 compared with maintained treatment with originator infliximab (NOR-SWITCH): a 52-week, randomised, double-blind, non-inferiority trial

Kristin Kaasen Jørgensen, Inge Christoffer Olsen, Guro Løvik Goll et al. · The Lancet · 2017 · 789 citations

Oncology, Clinical Translation, Originator Infliximab +10